5-Chloroacetyl-6-chlorooxindole

We are 5-Chloroacetyl-6-chlorooxindole CAS:118307-04-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 5-Chloroacetyl-6-chlorooxindole
CAS.NO:  118307-04-3
Synonyms:
6-Chloro-5-(chloroacetyl)-1,3-dihydro-2H-indol-2-one
6-chloro-5-(2-chloroacetyl)-1,3-dihydroindol-2-one

Molecular Formula: C10H7Cl2NO2
Molecular Weight:  244.07400

Physical and Chemical Properties:
Density: 1.471g / cm3
Boiling point: 439.1ºC at 760mmHg
Melting point: 202-206ºC
Flash point: 219.4ºC
Refractive index: 1.603

Specification:
Appearance: Light Brown Solid
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Ziprasidone hydrochloride CAS:122883-93-6
Intermediates of Ziprasidone mesilatel CAS:199191-69-0
Intermediates of ZiprasidoneCAS:146939-27-7

Related News: This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.Uridine 5'-Diphosphoglucose Disodium Salt Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.2,6-Diaminopyridine sulfate CAS:146997-97-9 The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.Ethyl 2-(1-Imidazolyl)acetate CAS:17450-34-9 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.